Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(CSE: BNXT )

0.3800 -0.0200 (-5.00%)
Streaming Delayed Price Updated: 9:30 AM EDT, May 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,000
Open 0.3800
Bid (Size) 0.3800 (2,000)
Ask (Size) 0.4200 (7,000)
Prev. Close 0.4000
Today's Range 0.3800 - 0.3800
52wk Range 0.2500 - 0.7500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
Via ACCESSWIRE
BioMedNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
-30.91%
-30.91%
1 Month
-18.28%
-18.28%
3 Month
-41.54%
-41.54%
6 Month
-5.00%
-5.00%
1 Year
-37.70%
-37.70%

More News

Read More
BioNxt Reports Successful Results From ODF Cladribine PK Study
Via ACCESSWIRE
BioNxt Reports Successful Results From ODF Cladribine Toxicity Study
Via ACCESSWIRE
BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
Via ACCESSWIRE
BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
Via ACCESSWIRE
BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
Via ACCESSWIRE
BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
Via ACCESSWIRE
BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
Via ACCESSWIRE
BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease
Via ACCESSWIRE
BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease
Via ACCESSWIRE
BioNxt Successfully Completes Pilot Study for Contract Development Customer
Via ACCESSWIRE
BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company
Via ACCESSWIRE
BioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing Capacity
Via ACCESSWIRE
BioNxt Solutions Acquires Novel Precision Drug Coating and Delivery Technology
Via ACCESSWIRE
BioNxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson’s Disease
Via ACCESSWIRE
BioNxt Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease
Via ACCESSWIRE
InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) to Expand Portfolio with Precision Drug Delivery Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioNxt Solutions Signs Term Sheet for Novel Precision Drug Coating Platform Technology
Via ACCESSWIRE
InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) Holds Key Meetings, Advances Product at Frankfurt CPHI Conference
Via Investor Brand Network
Topics Supply Chain
Exposures COVID-19 Supply Chain
BioNxt Solutions Reports on Frankfurt CPHI Conference
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.